Questions & explanations
1. How do researchers distinguish between a true vaccine-induced autoimmune event and a coincidental occurrence?
Researchers use epidemiological studies to compare the rate of autoimmune disease in vaccinated versus unvaccinated populations. If the rate is significantly higher in the vaccinated group within a specific time window after vaccination, it suggests a possible link. They also look for biological plausibility, such as identifying a mechanism like molecular mimicry. Additionally, they consider whether the autoimmune condition has a known genetic or environmental trigger that could coincide with vaccination. Large-scale safety monitoring systems, like the Vaccine Adverse Event Reporting System (VAERS), help detect rare events. Most associations found are not causal, and the risk is usually far lower than the risk from the disease itself.
2. Compare TLR agonists and emulsion adjuvants in terms of how they boost immunity.
TLR agonists (like CpG or monophosphoryl lipid A) directly activate specific toll-like receptors on immune cells, mimicking pathogen components. This triggers a targeted signaling cascade that produces cytokines and enhances antigen presentation. Emulsion adjuvants (like MF59 or AS03) are oil-in-water droplets that create a depot at the injection site, slowly releasing antigen and attracting immune cells. They also cause local inflammation, which recruits dendritic cells. While TLR agonists provide a more specific signal, emulsions provide a broader physical and inflammatory boost. Both increase antibody and T cell responses, but TLR agonists can be tailored to induce a particular type of immunity.
3. How does desensitization (lowering antibody levels before transplant) work, and give an example of a protocol used?
Desensitization aims to reduce harmful antibodies in the patient's blood before transplant. One common protocol uses plasmapheresis (filtering blood to remove antibodies) combined with low-dose intravenous immunoglobulin (IVIG, which contains antibodies that block immune activation). The patient undergoes several sessions of plasmapheresis, each followed by IVIG infusion. This lowers antibody levels temporarily, allowing a transplant from a donor with incompatible HLA. After transplant, the patient continues immunosuppression to prevent rebound antibody production. Success rates are lower than for non-sensitized patients, but it offers a chance for those with no other options.
4. How can a person's gut bacteria affect how well a vaccine works?
The gut microbiome, the community of bacteria living in the intestines, can influence vaccine responses. Certain gut bacteria help activate immune cells that are needed for a strong response to vaccination. For example, some bacteria produce molecules that signal the immune system to produce more antibodies. People with a diverse and healthy gut microbiome often show better antibody responses to vaccines like the oral polio or influenza vaccine. In contrast, an unbalanced microbiome, perhaps due to antibiotics or poor diet, may weaken vaccine effectiveness. This is why researchers are studying whether adding probiotics or specific fibers can improve vaccine outcomes.
5. Compare the effects of targeting CSF1R versus blocking CSF1 on tumor-associated macrophages.
Targeting CSF1R blocks the receptor on macrophages, so even if CSF1 is present, the signal is stopped. This kills many TAMs and reduces their suppressive functions. Blocking CSF1 (the ligand) also reduces signaling but may be less effective because other ligands like IL-34 can also activate CSF1R. CSF1R inhibitors affect both CSF1 and IL-34 signals, so they are more complete. However, blocking CSF1 might spare some macrophages that depend on IL-34, potentially causing fewer side effects. Both approaches aim to deplete M2-like TAMs and increase M1-like cells. Clinical trials show CSF1R inhibitors can be effective in certain cancers like tenosynovial giant cell tumor.
6. Compare the regulatory requirements for a new mRNA vaccine versus a new viral vector vaccine in terms of stability testing.
Both require stability testing to ensure the vaccine remains effective over time, but the conditions differ. mRNA vaccines are very sensitive to temperature; they often need ultra-cold storage (-70°C), so regulators require data showing stability at those temperatures and after thawing. Viral vector vaccines are generally more stable but may need freezing or refrigeration. Regulators require real-time and accelerated stability studies for both. For mRNA, they also test the integrity of the mRNA molecule over time. For viral vectors, they test the vector's ability to infect cells after storage. Both must show that potency is maintained throughout the shelf life.
7. What is a theoretical mechanism by which a vaccine could trigger autoimmunity?
One theoretical mechanism is molecular mimicry, where a vaccine antigen resembles a self-protein. The immune system, primed against the vaccine, may then mistakenly attack the body's own tissues. For example, a vaccine containing a protein similar to heart muscle could theoretically lead to myocarditis. Another mechanism is bystander activation, where vaccine-induced inflammation activates self-reactive immune cells that were previously dormant. Adjuvants that strongly stimulate the immune system might also break tolerance, causing the immune system to attack self-antigens. However, such events are extremely rare and usually require a genetic predisposition.
8. Why might a person who took antibiotics just before vaccination have a weaker immune response?
Antibiotics kill many gut bacteria, including beneficial ones that support immune function. This reduction in microbiome diversity can impair the body's ability to mount a strong vaccine response. For instance, after antibiotics, levels of bacteria like Bifidobacterium drop, which may lower antibody production. Additionally, the loss of certain bacteria can reduce the activation of dendritic cells, which are crucial for presenting vaccine antigens to T cells. As a result, the vaccine may not generate as many memory cells, leading to shorter protection. This is why doctors sometimes advise waiting to vaccinate until after completing antibiotics.
9. What is the main goal of neoantigen prediction algorithms?
Neoantigen prediction algorithms aim to find which mutated proteins in a tumor can be recognized by T cells. They analyze tumor DNA or RNA sequences to identify mutations that create new peptide sequences. These peptides must bind to the patient's MHC molecules (proteins that present fragments to T cells). The algorithms predict binding strength and immunogenicity (ability to trigger an immune response). This helps select personalized vaccine targets or T cell therapies. The process involves steps like mutation calling, peptide-MHC binding prediction, and ranking candidates. Accurate prediction is crucial for effective cancer immunotherapy.
10. Compare how the gut microbiome affects injected vaccines versus oral vaccines.
For oral vaccines, the gut microbiome directly interacts with the vaccine because the vaccine passes through the intestines. A healthy microbiome helps train immune cells in the gut to respond, leading to stronger mucosal immunity. For injected vaccines, the microbiome's effect is indirect: gut bacteria influence overall immune system balance and inflammation levels, which can affect how well the body responds to an injection. For example, a diverse gut microbiome is linked to better antibody responses to injected influenza vaccine. However, the impact is usually stronger for oral vaccines because they rely on gut-associated immune tissues.
11. Give an example of how M2 macrophages can be reprogrammed to M1-like to fight cancer.
One way is to use a drug that blocks CSF1R, like PLX3397 (pexidartinib). This reduces the survival signal for M2 macrophages. Another approach is to deliver signals like IFN-γ (a cytokine that promotes M1) directly into the tumor. Nanoparticles carrying TLR agonists (like CpG) can also switch macrophages to M1. For example, in mouse models, injecting a CD40 agonist antibody activates macrophages to become tumoricidal. These reprogrammed macrophages then produce nitric oxide and TNF-α to kill cancer cells. They also present antigens better and recruit T cells. Combining reprogramming with checkpoint inhibitors can boost anti-tumor immunity.
12. How can drug pricing policies affect access to immunotherapy globally?
High drug prices set by pharmaceutical companies limit access, especially in poor countries. Some countries negotiate lower prices or use generic versions to make drugs affordable. International organizations like the WHO may help by encouraging voluntary licensing, where companies allow cheaper production in poor countries. Price controls or compulsory licensing (where a government allows generic production without the company's consent) can also lower costs. However, these policies can be controversial because they may reduce company profits and future innovation. Balancing fair access and incentives for new drugs is a global challenge.